Abstract
A clinical study on grepafloxacin, a new sythetic antimicrobial quinolone derivative, was performed with the following results:
1. Pharmacokinetics
In order to examine the renal elimination mechanism of GPFX, the pharmacokinetics were compared between single-dose and probenecid-combined groups in 6 adult male volunteers using a cross-over method. It was found that the plasma and urinary concentrations of GPFX were not influenced by probenecid. The renal elimination mechanism of GPFX was thus estimated to depend mainly on glomerular filtration.
2. Clinical results
The efficacy and safety of GPFX were examined in 7 outpatients, including 3 cases of urinary infection and 4 cases of respiratory infection. The clinical result was excellent in all 3 cases of urinary infection and 2 cases of respiratory infection. The remaining 2 cases of respiratory infection responded effectively. Although no adverse reaction was noted, slightly increased GOT and GPT levels were observed as abnormal laboratory values in 1 case only.
